Nami Surgical

Advancing Robotic-Assisted Surgery.

Nami Surgical, a dynamic spin-out from the University of Glasgow’s Centre for Medical and Industrial Ultrasonics (C-MIU), is spearheading the evolution of ultrasonic surgery. With a mission to enhance patient outcomes worldwide, Nami is developing cutting-edge, miniaturised ultrasonic scalpels tailored for Robotic Assisted Surgery (RAS).

Despite the growing popularity of RAS in specialties like urology, gynaecology, and cardiology, its effectiveness was hindered by the bulky size of traditional ultrasonic scalpels, limiting their use in robotic procedures.

Nami Surgical’s breakthrough technology has revolutionised the RAS market with a novel ultrasonic platform. This innovation enables surgeons to conduct faster, safer robotic procedures, broadens the scope of RAS, and leverages the clinical benefits of ultrasonic devices to significantly improve patient outcomes.

Impact.

Nami’s high-performance, miniaturised ultrasonic scalpel overcomes substantial barriers in RAS. Robotic surgeries now promise reduced patient trauma, less post-operative pain, and quicker recovery times, contributing to shorter hospital stays. As the global market for robotic surgery is projected to reach $36 billion by 2032, Nami’s pioneering technology is setting new standards in surgical care.

Funding and Future Developments.

In May 2024, Nami Surgical secured a £3.2 million investment and grant funding. It benefitted from a £2.5m seed round led by Eos Advisory alongside the Investment Fund for Scotland, which is managed by UK private equity firm Maven and delivered by British Business Bank, Scottish Enterprise, and SIS Ventures. The company was separately awarded a £700,000 grant from Innovate UK, the UK’s national innovation agency.

He continued: “Medical ultrasound was first demonstrated in Glasgow in the 1950s and this led to the first ultrasound device going into service in 1965, so we’re proud to be a pioneering ultrasound startup developing technology that will enable a global market to innovate and to be doing that from a base in Scotland.”

Looking ahead, Nami Surgical will relocate to a new headquarters that will include a cutting-edge R&D prototyping lab as it expands its technical team to ten new members. The overall goal has always been to push the limits of miniaturisation in ultrasonic surgery, and along these lines, it has a product pipeline that includes ultrasonic scalpels designed for robotic-assisted surgery, smart ultrasonic generators, and hand-held ultrasonic scalpels tailored for laparoscopic procedures.

Collaboration and Leadership. 

Nami Surgical values close collaboration with clinicians and industry partners to transform their needs into innovative devices that enhance patient care and advance ultrasonic surgery. The company’s leadership, including Chief Technical Officer Dr Rebecca Cleary and Non-Executive Director Albert Nicholl, is dedicated to driving growth and innovation in the surgical field.

As a leading force in ultrasonic surgical technology, Nami Surgical is not only improving patient care but also shaping the future of surgery through its commitment to innovation and collaboration.